News from tapimmune inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 20, 2015, 08:30 ET

TapImmune to Present Clinical & Scientific Update at the 2015 Marcum Microcap Conference

TapImmune (OTCQB:TPIV), a clinic stage Cancer Immunotherapy Company, announced today that Dr. Glynn Wilson will present at the 2015 Marcum MicroCap...

May 15, 2015, 08:30 ET

Phase I Study in Ovarian & Breast Cancer Published in Abstracts of 2015 ASCO Annual Meeting

   TapImmune, Inc. (OTCQB: TPIV),  is pleased to announce that an Abstract on a Phase I Study on the Safety and Immunogenicity of...

Mar 30, 2015, 18:33 ET

Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"

TapImmune Inc. (OTCQB: TPIV), wishes to provide clarification on its participation at the Fifth Annual "Cancer Immunotherapy: A Long-Awaited...

Mar 25, 2015, 09:58 ET

TapImmune to Present at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" on Thursday March 26, 2015

TapImmune Inc. (OTCBB: TPIV), a clinical stage immunotherapy company specializing in the development of innovative technologies for the treatment of...

Mar 19, 2015, 08:45 ET

TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors

TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company's Board of Directors. David brings 30...

Mar 10, 2015, 08:30 ET

TapImmune Receives $1,000,000 from Strategic Investor

TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a US$1 million investment from Eastern Capital Limited under the same terms as the recent...

Feb 25, 2015, 08:45 ET

TapImmune Appoints John Bonfiglio as Strategic Advisor

TapImmune Inc. (OTCBB: TPIV) has pleasure in announcing the appointment of John Bonfiglio, Ph.D., MBA as a Strategic Advisor.  John is a...

Feb 23, 2015, 08:45 ET

TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer

TapImmune, (OTCBB: TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including...

Feb 20, 2015, 09:00 ET

TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015

TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and...

Feb 19, 2015, 09:30 ET

TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations

 TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer...

Jan 12, 2015, 09:19 ET

Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials

 TapImmune Inc. (OTCQB: TPIV) is extremely pleased to report the completion of data analysis from all 21 evaluable patients treated in a Phase...

Jan 12, 2015, 08:48 ET

TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering

TapImmune, Inc. (the "Company"), (otcqb:TPIV), today announced that it has entered into a definitive agreement with institutional investors for a...

Nov 24, 2014, 09:06 ET

TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews

TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the  following press articles published recently in which TapImmune...

Nov 18, 2014, 10:00 ET

TapImmune Announces Phase II Clinical Trials Collaboration With VGTI Florida to Advance Breast and Ovarian Cancer Vaccines

TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of...

Mar 20, 2013, 09:00 ET

TapImmune Announces the Appointment of Sherry Grisewood to the Board of Directors

TapImmune Inc. (OTCQB: TPIV) has pleasure in announcing the appointment of Sherry Grisewood, CFA to the Board of Directors. She has over 25...

Mar 13, 2013, 09:00 ET

TapImmune Inc. to Present at the Florida Road Show Conference on March 14, 2013

 TapImmune Inc. ("TapImmune" or the "Company") (OTCQB: TPIV), an immunotherapy company focused on the development of novel peptide and...

Jan 22, 2013, 09:00 ET

Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.

 TapImmune Inc. (OTCBB: TPIV) is pleased to announce the January publication of a paper titled "Enzymatic Discovery of a HER-2/neu Epitope That...

Jan 09, 2013, 09:00 ET

Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated with HER2/neu Antigens

 TapImmune Inc. (OTCBB: TPIV) has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu...